|
|
|
시장보고서
European Alzheimer's Disease (AD) Therapeutics Markets
|
Abstract
This Frost & Sullivan research service titled European Alzheimer' s Disease
(AD) Therapeutics Markets provides a detailed analysis of the AD therapeutics
markets in Europe. It includes qualitative aspects such as market challenges,
drivers and restraints, as well as forecasts of the overall market, and
individual market segments. This study also offers a detailed analysis of
existing products in the market, product pipelines of leading companies, and
strategic recommendations to market participants. Table of Contents
1. Executive Summary
- 1. Summary of the European Alzheimer' s Disease (AD) Therapeutics Market
- 1. Key Features of the European Alzheimer' s Disease (AD) Therapeutics
Market
2. Glossary of Terms
- 1. List of Terms
- 1. Abbreviations for the European AD Therapeutics Market
3. Market Engineering Research Methodology
- 1. Description of Research Methodology
- 1. Research Methodology for the European AD Therapeutics Market
4. Industry Challenges
- 1. Challenges and Issues
- 1. Main Challenges Facing the European AD Therapeutics Market
5. Market Engineering Research of the European Alzheimer' s Disease Therapeutics Market
- 1. Forecasts of the Overall Market
- 1. Introduction
- 2. Disease Burden
- 3. Prevalence and Incidence
- 4. Pharmacological Treatment Options
- 5. Market Engineering Measurements
- 6. Market Drivers
- a. Ageing Population Demographics
- b. High Level of Unmet Clinical Needs
- c. Memantine Fuelling Overall Market Growth
- d. Increasing Promotional Efforts
- 7. Market Restraints
- a. Low Level of Reimbursement for AD Therapeutics
- b. Negative Implications of Reference Pricing
- c. High Degree of Risk Associated with AD R&D
- d. Lack of Strong Clinical Guidelines Regarding the Expanded Usage of
AD Therapeutics
- 8. Revenue Forecasts
- 9. Geographic Trends
- 10. Segment-wise Trends
- 11. Competitive Structure
- 12. Market Share Analysis
6. Segment-wise Trends
- 1. Acetyl Cholinesterase (AChEI) Inhibitors
- 1. Market Overview
- 2. Market Engineering Measurements
- 2. N-methyl D-aspartate (NMDA) Receptor Antagonists
- 1. Market Overview
- 2. Market Engineering Measurements
7. Opportunities by Geographic Region
- 1. Opportunities in France
- 1. Market Overview
- 2. Market Engineering Measurements
- 3. Pricing and Reimbursement
- 2. Opportunities in Germany
- 1. Market Overview
- 2. Market Engineering Measurements
- 3. Pricing and Reimbursement
- 3. Opportunities in Spain
- 1. Market Overview
- 2. Market Engineering Measurements
- 3. Pricing and Reimbursement
- 4. Opportunities in the United Kingdom
- 1. Market Overview
- 2. Market Engineering Measurements
- 3. Pricing and Reimbursement
- 5. Opportunities in Italy
- 1. Market Overview
- 2. Market Engineering Measurements
- 3. Pricing and Reimbursement
8. Brand Analysis
- 1. Analysis of leading Brands in the World AD Therapeutics Market
- 1. Aricept
- 2. Reminyl
- 3. Exelon
- 4. Ebixa
9. Global Research and Development Activities
- 1. Promising Research in AD Therapeutics
- 1. Research and Development Area of Focus
- 2. Acetyl Cholinesterase Inhibitors
- 3. Estrogen Replacement Therapy/Hormone Replacement Therapy
- 4. Nerve Growth Factors
- 5. Other Approaches
10. Pipeline Insight
- 1. AD Therapeutics in Various Phases of Development
- 1. Analysis by Phase of Development
- 2. AD Therapeutics by Company
- 1. Astrazeneca
- 2. Elan Corporation Plc
- 3. Glaxosmithkline
- 4. Merck & Co Inc.
- 5. Myriad Genetics Inc.
- 6. Neuropharma S.A.
- 7. Novartis AG
- 8. Sanofi-Aventis
- 9. Wyeth
11. Strategic Recommendations
- 1. Strategies for the European AD Therapeutics Market
- 1. Recommendations to Participants
12. Decision Support Databases
- 1. DSD Tables
- 1. Prevalence of Dementia
- 2. Prevalence of Alzheimer' s Disease
- 3. Mortality of Alzheimer' s Disease
- 4. Male Population above 65 Years
- 5. Female Population above 65 Years
- 6. Number of Beds in Psychiatric Hospitals
- 7. Number of Physicians
List of Figures
Chapter 4
- AD Therapeutics Market: Impact of Top Industry Challenges (Europe),
2006-2012
Chapter 5
- Total AD Therapeutics Market: EURODEM Prevalence Rates for Men and Women
in Nine Different Age Groups for Dementia (Europe), 1980-1990
- Total AD Therapeutics Market: Market Drivers Ranked in Order of Impact
(Europe), 2006-2012
- Total AD Therapeutics Market: Market Restraints Ranked in Order of Impact
(Europe), 2006-2012
- Total AD Therapeutics Market: Revenue Forecasts (Europe), 2002-2012
- Total AD Therapeutics Market: Per cent of Revenues by Geographic Region
(Europe), 2005
- Total AD Therapeutics Market: Per cent of Revenues by Segment (Europe),
2005
- Total AD Therapeutics Market: Competitive Structure (Europe), 2005
- Total AD Therapeutics Market: Market Shares and Revenue Growth Rates of
Leading Products (Europe), 2005
Chapter 8
- AD Therapeutics Market: Key Features of Aricept (World), 2005
- AD Therapeutics Market: Key Features of Reminyl (World), 2005
- AD Therapeutics Market: Key Features of Exelon (World), 2005
- AD Therapeutics Market: Key Features of Ebixa (World), 2005
Chapter 10
- AD Therapeutics Market: Number of Drugs in Various Stages of Development
(World), 2005
- AD Therapeutics Market: Product Pipeline of Astrazeneca International
(World), 2005
- AD Therapeutics Market: Product Pipeline of Elan Corporation Plc (World),
2005
- AD Therapeutics Market: Product Pipeline of Glaxosmithkline Inc., (World),
2005
- AD Therapeutics Market: Product Pipeline of Merck & Co., Inc. (World), 2005
- AD Therapeutics Market: Product Pipeline of Myriad Genetics, Inc. (World),
2005
- AD Therapeutics Market: Product Pipeline of Neuropharma, S.A., (World),
2005
- AD Therapeutics Market: Product Pipeline of Novartis AG (World), 2005
- AD Therapeutics Market: Product Pipeline of Sanofi-Aventis Group (World),
2005
- AD Therapeutics Market: Product Pipeline of Wyeth (World), 2005
Chapter 12
- Decision Support Database: Prevalence of Dementia in ' 000 (World),
1999-2006
- Decision Support Database: Prevalence of Alzheimer' s Disease in ' 000
(World), 1999-2006
- Decision Support Database: Mortality Due to Alzheimer (World), 1999-2006
- Decision Support Database: Total Male Population of Age 65 Years and Above
in Millions (World), 1999-2006
- Decision Support Database: Total Female Population of Age 65 Years and
Above in Millions (World), 1999-2006
- Decision Support Database: Number of Beds in Psychiatric Hospitals in ' 000
(World), 1999-2006
- Decision Support Database: Number of Physicians (World), 1999-2006
|
 |
